Aralez Gets FDA Approval Of YOSPRALA, To Expand Salesforce By 85-110 By Launch

Aralez Pharmaceuticals Inc ARLZ disclosed that the FDA has given its approval for its once-daily YOSPRALA for secondary prevention of cardiovascular and aspirin-related gastric ulcers. The company indicated that it would be adding 85 – 110 sales representatives to its sales team by the time it launches the product.

Aralez indicated that a commercial launch is planned in the first week of October in the United States. The company claimed an estimated 26.2 million American adults are at risk for secondary cardiovascular events.

Related Link: What's Going On With Aralez Pharmaceuticals?

The company pointed out that the secondary CV events happen among those affected by heart ailments and that those who had a heart attack have the higher risk of CV within the first six years of the first event. The company estimates about 200,000 patients having a second heart attack a year.

Aralez CEO Adrian Adams commented, "The approval of YOSPRALA marks a major achievement for Aralez and helps address the current public health dilemma around patient discontinuation of daily aspirin therapy, which has potentially serious consequences."

Following the news, the stock advanced $0.76, or 12.82 percent, to $6.16. It had been halted for trade form about 7:10 a.m. to 10:04 a.m. ET.